Intramyocellular lipid (IMCL) accumulation in skeletal muscle greatly contributes to lipid-induced insulin resistance. Because acetyl-coenzyme A (CoA) carboxylase (ACC) 2 negatively modulates mitochondrial fatty acid oxidation (FAO) in skeletal muscle, ACC2 inhibition is expected to reduce IMCL via elevation of FAO and to attenuate insulin resistance. However, the concept of substrate competition suggests that enhanced FAO results in reduced glucose use because of an excessive acetyl-CoA pool in mitochondria. To identify how ACC2-regulated FAO affects IMCL accumulation and glucose metabolism, we generated ACC2 knockout (ACC2 2/2 ) mice and investigated skeletal muscle metabolites associated with fatty acid and glucose metabolism, as well as whole-body glucose metabolism. ACC2 2/2 mice displayed higher capacity of glucose disposal at the whole-body levels. In skeletal muscle, ACC2 2/2 mice exhibited enhanced acylcarnitine formation and reduced IMCL levels without alteration in glycolytic intermediate levels. Notably, these changes were accompanied by decreased acetyl-CoA content and enhanced mitochondrial pathways related to acetyl-CoA metabolism, such as the acetylcarnitine production and tricarboxylic acid cycle. Furthermore, ACC2 2/2 mice exhibited lower levels of IMCL and acetyl-CoA even under HFD conditions and showed protection against HFD-induced insulin resistance. Our findings suggest that ACC2 deletion leads to IMCL reduction without suppressing glucose use via an elevation in acetyl-CoA metabolism even under HFD conditions and offer new mechanistic insight into the therapeutic potential of ACC2 inhibition on insulin resistance. (Endocrinology 159: 3007-3019, 2018) 
Intramyocellular lipid (IMCL) accumulation in skeletal muscle greatly contributes to lipid-induced insulin resistance. Because acetyl-coenzyme A (CoA) carboxylase (ACC) 2 negatively modulates mitochondrial fatty acid oxidation (FAO) in skeletal muscle, ACC2 inhibition is expected to reduce IMCL via elevation of FAO and to attenuate insulin resistance. However, the concept of substrate competition suggests that enhanced FAO results in reduced glucose use because of an excessive acetyl-CoA pool in mitochondria. To identify how ACC2-regulated FAO affects IMCL accumulation and glucose metabolism, we generated ACC2 knockout (ACC2 2/2 ) mice and investigated skeletal muscle metabolites associated with fatty acid and glucose metabolism, as well as whole-body glucose metabolism. ACC2 2/2 mice displayed higher capacity of glucose disposal at the whole-body levels. In skeletal muscle, ACC2 2/2 mice exhibited enhanced acylcarnitine formation and reduced IMCL levels without alteration in glycolytic intermediate levels. Notably, these changes were accompanied by decreased acetyl-CoA content and enhanced mitochondrial pathways related to acetyl-CoA metabolism, such as the acetylcarnitine production and tricarboxylic acid cycle. Furthermore, ACC2 2/2 mice exhibited lower levels of IMCL and acetyl-CoA even under HFD conditions and showed protection against HFD-induced insulin resistance. Our findings suggest that ACC2 deletion leads to IMCL reduction without suppressing glucose use via an elevation in acetyl-CoA metabolism even under HFD conditions and offer new mechanistic insight into the therapeutic potential of ACC2 inhibition on insulin resistance. (Endocrinology 159: 3007-3019, 2018) I nsulin resistance, a primary determinant of type 2 diabetes, is associated with abnormal lipid metabolism caused by prolonged overnutrition. Emerging evidence suggests that ectopic lipid accumulation in insulin-target tissues triggers whole-body insulin resistance (1) (2) (3) . In particular, lipid accumulation in skeletal muscle, which serves as a primary site of insulin-stimulated glucose disposal, has a strong association with insulin resistance (3) (4) (5) (6) . Intramyocellular lipid (IMCL) content in skeletal muscle is negatively correlated to whole-body insulin sensitivity (3, 6) , with the exception of athletes (7) . Recent studies have shown that IMCL species such as ceramides and diacylglycerols directly impair insulin signaling pathways in skeletal muscle and are closely associated with the development of type 2 diabetes (8) (9) (10) (11) . Thus, reducing IMCL content in skeletal muscle is considered a potential approach for treating of type 2 diabetes.
Acetyl-coenzyme A (CoA) carboxylase (ACC), the enzyme that catalyzes production of malonyl-CoA from acetyl-CoA, is a key regulator in lipid metabolism. There are two molecularly and functionally distinct isoforms of ACC: ACC1 and ACC2. ACC1 is mainly expressed in lipogenic tissues and promotes de novo fatty acid synthesis by providing malonyl-CoA substrate in cytosol (12, 13) . On the other hand, ACC2 is mainly expressed in oxidative tissues such as skeletal muscle and negatively regulates fatty acid oxidation (FAO) at the mitochondrial membrane (12) (13) (14) . Malonyl-CoA produced by ACC2 allosterically inhibits carnitine palmitoyltransferase 1 (CPT1), the enzyme that catalyzes the conversion of long-chain acyl-CoA species to their mitochondrial membrane-permeable acylcarnitine esters at the outer mitochondrial membrane and promotes the entry of long-chain acyl-CoAs into mitochondria for FAO (15) . Considerable evidence suggests that reduced skeletal muscle FAO capacity potentially contributes to IMCL accumulation and insulin resistance (5, (16) (17) (18) , and enhanced skeletal muscle FAO flux is sufficient to reduce IMCL content and prevent lipid-induced insulin resistance (19, 20) . Because ACC2 negatively regulates mitochondrial FAO through CPT1 inactivation, ACC2 inhibition is thought to reduce IMCL accumulation by enhancing FAO and then to alleviate insulin resistance. Indeed, previous studies have reported that genetic or pharmacologic inhibition of ACC2 results in enhanced FAO, decreased lipid accumulation in skeletal muscle, and improved insulin sensitivity (21, 22) . Thus, enhancing the FAO pathway via ACC2 inhibition is an attractive potential strategy for the treatment of lipid-induced insulin resistance.
Over the past decade, however, the strategy of targeting FAO has been challenged by the theory based on substrate competition between glucose and fatty acids as an energy source. Randle et al. (23, 24) originally proposed the concept of the glucose-fatty acid cycle as a substrate competition model, providing a potential mechanism for lipid-induced insulin resistance. In this concept, increasing the supply and oxidation of fatty acids causes mitochondrial accumulation of acetyl-CoA, which is the final product of the FAO cycle. Acetyl-CoA allosterically inhibits pyruvate dehydrogenase, a key enzyme in glycolysis and glucose oxidation, and thus acetyl-CoA accumulation leads to suppression in glucose metabolism. Recently, mice lacking muscle-specific carnitine acetyltransferase (CrAT), which converts acetyl-CoA to acetylcarnitine, were found to have impaired substrate switching and glucose intolerance (25) , supporting the mitochondrial acetyl-CoA pool as a potential cause of substrate competition and glucose metabolism dysfunction. Therefore, the strategy designed to accelerate FAO for treating lipid-induced insulin resistance requires careful consideration of acetyl-CoA accumulation. Although several studies have explored the role of ACC2 in energy metabolism, it remains elusive how ACC2-regulated FAO affects IMCL deposition, the acetyl-CoA pool, and glucose metabolism.
Here, we generated ACC2 knockout (ACC2 2/2 ) mice and performed deep analysis of skeletal muscle metabolites associated with mitochondrial FAO, as well as evaluation of whole-body glucose metabolism. Our results provide evidence that ACC2 deletion enables IMCL reduction without suppressing glucose metabolism due to elevated acetyl-CoA metabolism and attenuates high-fat diet (HFD)-induced insulin resistance.
Materials and Methods
Generation of ACC2 2/2 mice ACC2 floxed mice were generated by Unitech (Kawasaki, Japan). Briefly, homologous recombination was performed on mouse embryonic stem cells derived from the C57BL/6J strain using a targeting vector (Fig. 1A) . Homologous recombination was confirmed by Southern hybridization (data not shown). Chimera mice were generated by microinjection of embryonic stem cells into blastocysts derived from BALB/c mice. For removal of the Neo cassette, the targeted mice were crossed with Flpe transgenic mice [C57BL/6-Tg(CAG-flpe)36Ito/ItoRbrc; RIKEN Bio Resource Center, Tsukuba, Japan] (26). For systematic gene disruption, the floxed mice were crossed with Cre transgenic mice [C57BL/6-Tg (CMV-cre)1Cgn/J; The Jackson Laboratory, Bar Harbor, ME] (27) , and then the Cre gene was removed by crossing with C57BL/ 6J mice. Homozygous ACC2 2/2 mice and wild-type (WT) control mice were derived from the identical heterozygous mice and bred by homozygous cross in each. Genotyping was performed by PCR with genomic DNA extracted from their tails using KOD FX DNA polymerase (Toyobo, Osaka, Japan) with the following primers: WT allele (280 bp) and floxed allele (450 bp), 5 0 -AGGACT-GTCCTGCCTATGCA-3 0 (forward) and 5 0 -AACGAGGT-AAAGATGTCCAGTCTG-3 0 (reverse); KO allele (650 bp), 
Animal studies
Animal studies were conducted in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International, and all procedures for the studies were approved by the Institutional Animal Care and Use Committee of Shionogi & Co. (Osaka, Japan). All studies were performed with male, age-matched ACC2 2/2 and WT mice. Mice were housed individually in a temperaturecontrolled (20°C to 23°C) environment under a 12-hour light/dark cycle with ad libitum access to a normal chow diet (CE-2; CLEA Japan, Tokyo, Japan) and water. For high-fat feeding experiments, mice at the age of 8 to 9 weeks were fed a 60% HFD (58Y1; Test Diet, St. Louis, MO) for 3 months. The composition of the diets used in this study is provided in Supplemental Table 1 . For enzyme activity measurements and metabolite profiling in skeletal muscle, mice were euthanized 5 to 6 hours after food removal and the quadriceps muscles were rapidly dissected. Muscle samples were frozen immediately in liquid nitrogen and stored at 280°C before analysis.
Gene expression
Total RNA was extracted from the tissues using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. First-strand complementary DNA was synthesized using a High-Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA). Quantitative PCR assays were performed on a 7500 Real-Time PCR system (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems). Gene expression levels were calculated after normalization to the housekeeping gene b-actin using the 2 -DDCt method and expressed as relative to WT mice. 
Whole-body FAO
Whole-body FAO was assessed using an open-circuit metabolic gas analysis system connected directly to a mass spectrometer (Arco 2000; Arco System, Chiba, Japan), as previously described (28) . At the age of 11 weeks, mice were placed in individual metabolic chambers. After 4 days of acclimation to the metabolic chamber, FAO capacity was examined by exogenous administration of 13 C-labeled oleic acid. Mice were orally administered 15 ml/kg of a liquid diet (F2LCW; Oriental Yeast, Tokyo, Japan) with 13 C-labeled oleic acid (Cambridge Isotope Laboratories, Andover, MA). After the administration, the 13 CO 2 -to-12 CO 2 ratio in respiratory gas was measured every 5.5 minutes over 3 hours. The liquid diet was prepared to a concentration of 4.95 g/15mL, and 13 C-labeled oleic acid was added to the diet to a final concentration of 0.04 mol/L. During the study, mice were fasted with free access to water.
Blood metabolic parameters
Blood samples were collected from the tail vein after a 6-hour fast. Plasma glucose, triglyceride, and nonesterified fatty acid concentrations were determined by enzymatic methods using a Hitachi 7180 automatic analyzer (Hitachi, Tokyo, Japan). Plasma insulin concentration was measured using a mouse insulin ELISA kit (Shionogi, Osaka, Japan) (29) .
Glucose and insulin tolerance tests
Mice were fasted for 4 hours and injected intraperitoneally with either glucose (1 g/kg) or Humulin R (0.25 U/kg; Eli Lilly, Kobe, Japan). A glucometer (Arkray, Tokyo, Japan) was used to measure blood glucose concentrations in tail-vein samples.
Intramyocellular and extramyocellular lipid measurements
IMCL and extramyocellular lipid (EMCL) levels were measured using magnetic resonance spectroscopy. All in vivo magnetic resonance (MR) experiments were performed on a Varian MRI System 7T/210 (Agilent Technologies, Santa Clara, CA). A circular (24-mm diameter) 1 H surface coil (Doty Scientific, Columbia, SC) was used for radiofrequency transmission and reception. Mice were anesthetized with 2% isoflurane and their temperature was maintained at 37.0°C 6 0.5°C. Mice were placed supine on a plastic cradle, and the surface coil was placed on the tibialis anterior (TA) muscle of the left hind leg. For placement of the MR spectroscopy voxel in the TA muscle, axial gradient echo pilot images were acquired with the following parameters: repetition time, 200 ms; echo time, 4.0 ms; flip angle, 20°; four averages; field of view, 12.8 3 12.8 mm 2 ; eight slices; slice thickness, 1.0 mm; and matrix size, 128 3 128. Single-voxel MR spectra in the TA muscle were acquired using a point-resolved spectroscopy sequence with the following parameters: repetition time divided by echo time, 2000/15 ms; voxel size, 1.0 3 1.0 3 5.0 mm 3 ; 512 averages; variable pulse power and optimized relaxation delays (VAPOR) water suppression; and total acquisition time, 17 minutes. Unsuppressed water spectra (four averages) were recorded in the same voxel and were used as an internal reference. All spectroscopy data were analyzed using the LCModel, version 6.3, software package. IMCL and EMCL values were calculated as the ratio to total creatine.
Glycogen content
Quadriceps muscles were rapidly dissected and frozen immediately with liquid nitrogen. The sample preparations and glycogen content measurements were performed using the commercial Glycogen Assay Kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions.
Insulin sensitivity
Whole-body insulin sensitivity was assessed by the hyperinsulinemic-euglycemic clamp. Mice were anesthetized with isoflurane and catheters were inserted into the right jugular vein for infusion of insulin and glucose. After overnight fasting, mice received continuous infusion of insulin (10.5 mU/kg/min Humulin R), and blood samples were collected from the tail vein at 10-minute intervals for immediate evaluation of blood glucose using a glucometer (Arkray). Glucose (25% solution in saline) was also infused at variable rates to maintain blood glucose levels at 5.6 to 6.7 mmol/L (100 to 120 mg/dL).
Muscle insulin sensitivity was assessed by insulin-stimulated Akt phosphorylation. After catheterization was performed, overnight-fasted mice were intravenously injected via the catheters with insulin (0.125 U/kg Humulin R) or saline. Mice were euthanized 3 minutes after insulin injection under pentobarbital anesthesia, and quadriceps muscles were rapidly dissected. Phosphorylated Akt protein was detected by western blot analysis.
Western blot analysis
Total protein of skeletal muscle and liver was prepared with lysis buffer with a protease and phosphatase inhibitor cocktail using standard techniques. Total protein was electrophoresed with SDS-PAGE gels and then transferred to polyvinylidene fluoride membrane. For ACC protein detection, membranes were probed with anti-ACC protein antibody (1:1000; catalog no. 3676; Cell Signaling Technology, Danvers, MA; RRID: AB_ 2219397) as a primary antibody and then horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antibody (1:20,000; catalog no. NA934; GE Healthcare, Little Chalfont, United Kingdom; RRID: AB_772206) as a secondary antibody. For GAPDH protein detection, membranes were probed with HRP-conjugated anti-GAPDH antibody (1:500; catalog no. 3683S; Cell Signaling Technology; RRID: AB_1642205). Protein signals were detected using enhanced chemiluminescence western blotting detection reagents (GE Healthcare). For Akt protein detection, membranes were probed with anti-Akt Ser473 antibody (1:1000; catalog no. 9271; Cell Signaling Technology; RRID: AB_329825) or anti-Akt antibody (1:1000; catalog no. 9272; Cell Signaling Technology; RRID: AB_329827) as a primary antibody and HRP-conjugated anti-rabbit IgG antibody (1:2000; catalog no. 7074; Cell Signaling Technology; RRID: AB_2099233) as a secondary antibody. Protein signals were detected using a Lumi GLO reagent (Cell Signaling Technology) and high-performance chemiluminescence film (GE Healthcare). The signals were quantified using the VersaDoc 5000MP Imaging System (Bio-Rad, Richmond, CA) and Quantity One software (Bio-Rad).
Enzyme activity measurements
Isocitrate dehydrogenase activity and citrate synthase activity were determined spectrophotometrically using the commercial Isocitrate Dehydrogenase Colorimetric Assay Kit (Abcam, Cambridge, MA) and Citrate Synthase Activity Colorimetric Assay Kit (BioVision, Mountain View, CA), respectively. Frozen muscle samples (50 to 100 mg) were homogenized in the assay buffers supplied with the commercial kits, using stainless steel beads and TissueLyser II (Qiagen). After centrifugation at 13,000g for 10 minutes (for the isocitrate dehydrogenase activity assay) or 10,000g for 5 minutes (for the citrate synthase activity assay), the supernatants were collected and the enzyme activities were measured spectrophotometrically according to the manufacturer's instructions.
For CrAT assays, frozen muscle samples (approximately 100 mg) were minced and homogenized in CelLytic MT lysis buffer (Sigma-Aldrich, St. Louis, MO), using stainless steel beads and TissueLyser II (Qiagen). After centrifugation at 13,000g for 10 minutes, the supernatants were used for measurements of CrAT activity and protein level. CrAT activity was measured spectrophotometrically at 412 nm by evaluating the rate of reduction of DTNB [5, 5 0 -dithiobis(2-nitrobenzoic)] by the free CoA liberated from acetyl-CoA, as previously described (25, 30) . CrAT protein level was measured using the commercial Mouse CRAT ELISA Kit (LifeSpan BioScience, Seattle, WA) in accordance with the manufacturer's instructions. In spectrophotometric assays, a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA) was used for absorbance reading.
Metabolite profiling in skeletal muscle
Measurements and data processing for glucose 6-phosphate, fructose 6-phosphate, and fructose 1,6-bisphosphate levels in quadriceps muscle samples were carried out through C-SCOPE analysis service at Human Metabolome Technologies (Yamagata, Japan). For determination of acyl-CoAs, tricarboxylic acid (TCA) cycle intermediates and other glycolytic intermediates, frozen muscles were powdered with 5-mm stainless steel beads using a ShakeMaster Auto machine (BioMedical Science, Tokyo, Japan). For C16-and C18-CoA measurements, the powdered muscle samples were homogenized in four volumes of tissue weight of methanol/water (75:25, v/v) containing 6% perchloric acid and 4% phosphoric acid. After the samples were centrifuged at 15,000g for 5 minutes, the supernatant was transferred into glass vials and liquid chromatography-mass spectrometry (LC-MS) analysis was performed using Nexera MP (Shimadzu, Kyoto, Japan) and QTRAP6500 (Sciex, Toronto, Canada). For acetyl-CoA, malonyl-CoA, TCA cycle intermediate, and glycolytic intermediate measurements, the powdered muscle samples were homogenized in four volumes of tissue weight of water containing 6% perchloric acid and 4% phosphoric acid. After the samples were centrifuged at 15,000g for 5 minutes, the supernatant was transferred into polypropylene vials and LC-MS analysis was performed using Nexera MP and API5000 (Sciex). Raw LC-MS data were analyzed using Analyst, version 1.6.2 (Sciex).
Acylcarnitine analysis
Plasma samples and quadriceps muscle samples were collected from 6-hour-fasted mice. For plasma acylcarnitine analysis, 2 mL of plasma was mixed with 400 mL of D9-C0-carnitine, D3-C16-carnitine (hereafter referred to as internal standard mixture) in methanol and subsequently vortexed. After the samples were centrifuged at 15,000g for 5 minutes, the supernatant was transferred into glass vials and LC-MS analysis was performed and raw LC-MS data analyzed as for muscle metabolomic profiling. For skeletal muscle acylcarnitine analysis, powdered quadriceps muscles samples were homogenized in 400 mL of methanol, using ShakeMaster Auto machine. The muscle homogenate was mixed with internal standard mixture in methanol and subsequently vortexed. After the samples were centrifuged at 15,000g for 5 minutes, the supernatant was transferred into glass vials and LC-MS analysis was performed using ultraperformance liquid chromatography (Waters, Milford, MA) and LTQ Orbitrap (Thermo Fisher Scientific, Austin, TX). Raw LC-MS data were analyzed using Xcalibur, version 2.2 (Thermo Fisher Scientific).
Statistical analysis
All results are presented as mean 6 SEM. Statistical comparisons between groups were analyzed by Welch t test. Statistical significance was set at P , 0.05.
Results

Targeted deletion of ACC2
To generate ACC2 2/2 mice, exons 15 through 18, which code for the biotin carboxylase domain, were targeted by homologous recombination (Fig. 1A) . ACC2 2/2 mice were created on a pure C57BL/6J genetic background. ACC2 is highly expressed in skeletal muscle, liver, and heart (12, 31, 32) , and is also reported to be expressed in adipose tissue (12, 33) . To confirm the lack of ACC2, we examined gene expression levels of ACC in these tissues from ACC2 mice by quantitative PCR analysis. We found that ACC2 expression was completely absent in these tissues from ACC2 2/2 mice (Fig. 1B ) and ACC1 expression levels were similar between ACC2 2/2 and WT mice (Fig. 1C) . Using western blot analysis with a monoclonal antibody recognizing both ACC1 and ACC2, we demonstrated that signals of ACC protein were greatly diminished in skeletal muscle from ACC2 2/2 mice as compared with WT mice (Fig. 1D) , whereas ACC protein was observed in liver, the predominant tissue of ACC1 expression, from both groups of mice (Fig. 1E) . Similarly, ACC2 2/2 mice showed a marked reduction in skeletal muscle malonyl-CoA (256%; P , 0.001; Fig. 1F ) and heart malonyl-CoA (268%; P , 0.001; Supplemental Fig. 1 ), which are mainly produced by ACC2, and a moderate reduction in liver malonyl-CoA (218%; P , 0.01), which is mainly produced by ACC1 (Fig. 1G) . The functional consequence of ACC2 deletion on whole-body FAO was assessed based on oxidation of exogenous fat. After oral ingestion of a fat diet with 13 C-labeled oleic acid, ACC2 2/2 mice exhibited a much greater increase in relative abundance of 13 CO 2 in expired air than WT mice, suggesting that ACC2 2/2 mice have a greater capacity of FAO at the whole-body level (Fig. 1H ).
ACC2 deletion enhanced glucose metabolism at the whole-body level Plasma glucose, triglyceride, and nonesterified fatty acid levels, as well as body weight, were similar between ACC2 2/2 and WT mice ( Fig. 2A-2D ), whereas plasma insulin levels were significantly lower in ACC2 2/2 mice (Fig. 2E ). To further investigate whole-body glucose metabolism in ACC2 deletion, we performed glucose and insulin tolerance testing. ACC2 2/2 mice were significantly tolerant to glucose overload, compared with WT mice (Fig. 2F) . Likewise, glucose disposal in response to insulin injection was greater in ACC2 2/2 mice (Fig. 2G) . These results suggest that ACC2 deletion does not induce impairment in substrate switching but leads to enhancement in whole-body glucose disposal.
ACC2 deletion diminished IMCL accumulation along with reduced acetyl-CoA content in skeletal muscle ACC2 2/2 mice showed significantly reduced levels of IMCL, whereas EMCL levels were similar between ACC2
2/2 and WT mice (Fig. 3A) . ACC2 2/2 mice showed significantly decreased levels of long-chain acyl-CoAs such as C16:0-, C18:0-, and C18:1-CoA (Fig. 3B) , markedly increased levels of long-chain acylcarnitines, and significantly decreased levels of free carnitine ( Fig. 3C and 3D ). These results support that acyl-CoA conversion to acylcarnitine esters is enhanced in ACC2-deleted skeletal muscle, and this enhanced acylCoA conversion promotes the entry of fatty acid into mitochondrial FAO and contributes to the lower IMCL levels of ACC2 2/2 mice.
Regarding glucose metabolism, no significant difference was observed in levels of glycolytic intermediates (Fig. 3E ) and glycogen stores (Fig. 3F ) between both groups of mice. Notably, acetyl-CoA levels in skeletal muscle were significantly decreased in ACC2 2/2 mice (38% lower than WT mice; P , 0.001; Fig. 3G ).
ACC2 deletion increased metabolite levels and enzyme activities related to acetyl-CoA metabolism in skeletal muscle
To explore the effect of ACC2 deletion on acetyl-CoA metabolism in skeletal muscle, we first evaluated metabolite levels and enzyme activities of the TCA cycle, a major consumer of acetyl-CoA in mitochondria. As compared with WT mice, ACC2 2/2 mice had significant increases in levels of most of TCA cycle intermediates in skeletal muscle (Fig. 4A ). Isocitrate dehydrogenase activity was significantly increased in ACC2 2/2 mice, whereas there was no difference in citrate synthase activity between both groups of mice ( Fig. 4B and 4C ). Acetylcarnitine production via CrAT is also known to consume acetyl-CoA as a substrate in mitochondria. Acetylcarnitine levels in skeletal muscle were significantly increased in ACC2 2/2 mice (92% higher than WT mice; P , 0.001; Fig. 3C ). We next evaluated CrAT-specific activity, which was reported to be fundamentally important for acetyl-CoA conversion into acetylcarnitine (30) . Total CrAT activity was reduced by 37% in muscle lysate of ACC2
2/2
mice as compared with WT mice (Fig. 4D) . On the other hand, CrAT protein levels were further reduced by 72% (Fig. 4E) . Thus, when CrAT activity was corrected for the protein level, the specific activity of the enzyme was significantly increased twofold, as compared with WT mice (Fig. 4F) . Because CrAT-mediated acetylcarnitine production in skeletal muscle can be reflected by acetylcarnitine efflux into blood (34), we measured plasma levels of acylcarnitines. Similar to skeletal muscle, plasma acetylcarnitine levels were significantly increased in ACC2 2/2 mice, whereas there were no differences in plasma medium-and long-chain acylcarnitine levels ( Fig. 4G and 4H ).
ACC2 deletion attenuated HFD-induced IMCL accumulation and insulin resistance
We also examined the effect of ACC2 deletion on energy metabolism under prolonged overnutrition, using ACC2 2/2 and WT mice fed an HFD. Body weight gain and white adipose tissue weight of ACC2 2/2 mice were significantly lower than those of WT mice ( Fig. 5A ; Supplemental Fig. 2A) . Food intake was similar between both groups of mice (Supplemental Fig. 2B ). There was a significant reduction in plasma insulin levels in ACC2
2/2 mice (Supplemental Table 2 ). Similar to a normal diet, ACC2 2/2 mice exhibited elevated whole-body glucose disposal in glucose tolerance testing and insulin tolerance testing (Supplemental Fig 2C and 2D) . For further investigation into insulin sensitivity, we performed the hyperinsulinemic-euglycemic clamp in body weight-matched ACC2 2/2 and WT mice (44.1 6 0.8 g and 45.0 6 1.1 g, respectively). Compared with WT mice, ACC2 2/2 mice showed a marked improvement in whole-body insulin sensitivity, as reflected by an approximately 1.8-fold increase in the steady-state glucose infusion rate to maintain euglycemia ( Fig. 5B and 5C ); plasma insulin levels in the clamp study were similar between both groups of mice (Fig. 5D ).
To evaluate tissue-specific insulin action, we examined the level of Akt phosphorylation in skeletal muscle. Insulin-stimulated Akt phosphorylation in skeletal muscle was significantly increased 1.6-fold in ACC2 2/2 mice as compared with WT mice (Fig. 5E) . Furthermore, ACC2 2/2 mice had increased insulin-stimulated glucose uptake in skeletal muscle but not liver or white adipose tissue (Supplemental Fig. 2E ). These results support that increased insulin sensitivity in skeletal muscle substantially contributes to improved whole-body glucose metabolism in ACC2 deletion. Previous studies in rodents have shown that HFD feeding can lead to dysfunction of acetyl-CoA metabolism, such as reduced TCA cycle intermediates (35) and impaired acetylcarnitine production (30) , in skeletal muscle. In the present study, HFD led to marked increases in skeletal muscle IMCL levels in both groups of mice, but ACC2 2/2 mice maintained significantly lower levels of IMCL than did WT mice (Fig. 6A ). Similar to a normal diet, ACC2 2/2 mice had significantly increased levels of acetylcarnitine and long-chain acylcarnitines ( Fig. 6B and 6C) . Furthermore, reduced levels of acetylCoA (55% lower than WT mice; P , 0.001; Fig. 6D ) and increased levels of TCA cycle intermediates (Fig. 6E) were evident in ACC2 2/2 mice. Taken together, skeletal muscle metabolite profiles of mice fed an HFD were similar to those of mice fed a normal diet.
Discussion
In this study, we aimed to reveal the role of ACC2-regulated FAO on IMCL deposition and glucose metabolism. We demonstrated that ACC2 2/2 mice did not have impaired glucose metabolism but did have higher capacity of whole-body glucose disposal under either glucose-or insulin-stimulated conditions. Our analysis of skeletal muscle revealed that ACC2 deletion enhanced acylcarnitine formation, which is required for the entry of long-chain fatty acids into mitochondrial FAO cycle, and diminished IMCL accumulation, but ACC2 deletion did not suppress the glycolytic pathway. Importantly, this IMCL reduction was accompanied, surprisingly, by a decrease in the acetyl-CoA pool in skeletal muscle of ACC2 2/2 mice. Moreover, the TCA cycle and acetylcarnitine production, two major pathways to consume the acetyl-CoA pool in mitochondria, were upregulated in skeletal muscle of ACC2 2/2 mice. Collectively, ACC2 deletion led to upregulation in acetyl-CoA metabolism and in long-chain acyl-CoA entry into mitochondrial FAO, and thereby enabled a marked reduction in IMCL without increasing the mitochondrial acetyl-CoA pool as a cause of suppression in glucose use (Fig. 7) .
The relationship between elevated FAO and impaired substrate switching becomes more apparent under HFD conditions, which lead to depletion of TCA cycle metabolites and impairment of acetyl-CoA conversion into acetylcarnitine in skeletal muscle (30, 35) . Our results show that TCA cycle and acetylcarnitine production properly function to decrease acetyl-CoA pool in ACC2-deleted skeletal muscle even under HFD conditions, and thus ACC2 deletion alleviates HFD-induced IMCL accumulation and the subsequent insulin resistance. The increased insulin-stimulated Akt phosphorylation and glucose uptake in skeletal muscle also support that ACC2 deletion does not impair glucose use as an energy substrate but leads to increased insulin sensitivity in skeletal muscle. In addition, we found that ACC2 2/2 mice had higher levels of long-chain acylcarnitines in skeletal muscle under both normal diet and HFD conditions. Although accumulation of long-chain acylcarnitines were reported to implicate excessive FAO in lipid-induced insulin resistance (36, 37) , our findings suggest that muscle acylcarnitine accumulation simply reflects enhanced FAO pathway and has no significant direct role in the development of insulin resistance. For decades, the concept of substrate competition has been supported by several lines of work showing that increasing lipid exposure and the corresponding FAO elevation impair the substrate shift to glucose, which, in turn, causes insulin resistance in skeletal muscle (23, 35, 38) . These studies imply that lipid-induced disruption in glucose metabolism is intimately associated with the imbalance between lipid supply and oxidative capacity in mitochondria, not with the elevated FAO pathway itself. Mitochondrial lipid overload beyond the limit of its oxidative capacity causes incomplete FAO, which is characterized by impairment of the TCA cycle function and accumulation of FAO-derived metabolites such as acetyl-CoA, and then impairs glucose metabolism. Accordingly, simply shifting substrate selection to fatty acids without expanding mitochondrial oxidative capacity would not improve glucose metabolism but cause incomplete FAO and substrate competition. Conversely, if enhancing FAO flux is coupled with a corresponding upregulation in the mitochondrial downstream processes, the system would relieve intramyocellular lipid stress and ameliorate insulin resistance (19, 39) . In the present study, ACC2 2/2 mice had decreased acetyl-CoA levels, increased TCA cycle activity, and reduced IMCL content in skeletal muscle. Furthermore, we observed increased whole-body oxygen consumption in ACC2 2/2 mice (Supplemental Fig. 3 ).
These findings indicate that the IMCL reduction in ACC2 deletion is adequately coupled with the mitochondrial downstream processes including the TCA cycle and respiratory chain. Notably, in addition to these mitochondrial metabolic processes, CrAT-mediated acetylcarnitine production and efflux facilitate acetyl-CoA trafficking in mitochondria and relieve suppression of glucose oxidation under lipid oxidative conditions (25, 30, 34) . Thus, acceleration of acetylcarnitine production is also most likely to have an important role in preventing mitochondrial incomplete FAO in ACC2 deletion. Taken together, the results of our study suggest that alterations of skeletal muscle lipid metabolism via ACC2 deletion are properly coordinated with the metabolism downstream of acetyl-CoA, leading to successful reduction of IMCL.
Compensatory upregulation of mitochondrial oxidative capacity occurs when there is increased lipid availability and elevated FAO in skeletal muscle (40, 41) . Thus, the upregulated mitochondrial processes in ACC2 deletion may be primarily attributed to the elevated FAO itself. In addition, the positive effects of acetylcarnitine on mitochondrial metabolic function have been reported (42, 43) , raising the possibility that upregulated CrATmediated acetylcarnitine production partly contributes to the increased capacity for mitochondrial substrate oxidation in ACC2 deletion. Interestingly, both CrAT and CPT1 belong to the family of carnitine acyltransferases and share similar catalytic domains (44) . Recently, long-chain acyl-CoAs were reported to potentially suppress CrAT activity (30) , similar to the suppression of CPT1 activity by malonyl-CoA. In the present study, we found that ACC2 deletion led to reductions in longchain acyl-CoAs and malonyl-CoA in skeletal muscle, prompting speculation that ACC2 plays an important role in regulation of both CPT1 and CrAT activities by affecting the intramyocellular acyl-CoA profile. Additional examination is required to identify the mechanism underlying upregulation of mitochondrial function in the absence of ACC2.
Our results are consistent with the previous findings by Choi et al., who reported that ACC2 2/2 mice are protected from HFD-induced insulin resistance (21) . In addition, a previous report of glucose-lowering effects by an ACC2 inhibitor supports our findings (22) . Other groups (45) (46) (47) , however, reported that their independently generated ACC2 2/2 mice exhibited metabolic phenotypes that conflict with those reported by 
Choi et al. (21). Olson et al. reported that deletion of ACC2
has little effect on glucose homeostasis (45) . Notably, they reported that deletion of ACC2 has no impact on even skeletal muscle malonyl-CoA content, which is inconsistent with not only our findings but also those of other studies on genetic ablation or pharmacological inhibition of ACC2. Because malonyl-CoA is a main regulator for ACC2-mediated lipid metabolism, this discrepancy may explain the phenotypic differences. Hoehn et al. (46) and Brandon et al. (47) reported that whereas deletion of ACC2 reduces malonyl-CoA content in skeletal muscle and enhances FAO at the whole-body level, the enhanced FAO is compensated by suppressing glucose use and consequently has no beneficial effect on glucose metabolism, as described in the substrate competition models. The reason for these phenotypic differences remains unclear. Hoehn et al. (48) have pointed out the possibility that overexpression of hypoxanthine-guanine phosphoribosyltransferase affected the phenotype in the ACC2 2/2 mice of Abu-Elheiga et al. (49) . In the present study, we generated ACC2 2/2 mice on a pure C57BL/6 genetic background using the Cre-LoxP system to target the biotin carboxylase domain, as did Hoehn et al. (46) , and we demonstrated that ACC2 deletion leads to improvement of whole-body glucose metabolism. Our results indicate that the beneficial effect of ACC2 deletion is reproducible regardless of genetic background and cloning strategy. More importantly, previous studies have shown beneficial effects of ACC2 deletion or inhibition but did not describe a convincing mechanism for avoiding substrate competition in skeletal muscle in the absence of ACC2 (21, 22) , raising potential concern about therapeutic efficacy of ACC2 inhibition (50, 51) . Thus, our current investigations, which revealed that ACC2-regulated FAO pathway has the proper mechanism to prevent acetylCoA accumulation in skeletal muscle, can contribute to the development of antidiabetic agents targeting ACC2. Future mechanistic studies using pharmacological approaches are needed to further support our findings. Last, although the results of our clamp study indicate that ACC2 deletion improves insulin sensitivity independently of weight loss, we found that ACC2 deletion prevented HFD-induced obesity, consistent with the report of Choi et al. (21) . Because weight loss can reduce insulin resistance in obese patients with diabetes, the antiobesity effect of ACC2 deletion is a noteworthy finding in the present study. The results of the previous report of Choi et al. (21) and our short-term HFD experiments (Supplemental Fig. 3 ) suggest increased energy expenditure may contribute to weight reduction in ACC2 deletion. Notably, elevated substrate oxidation and mitochondrial uncoupling in adipose tissue have been reported in ablation of ACC2 (52, 53) . Consistent with these reports, we found upregulated mRNA levels of uncoupling protein 2 in white adipose tissue from ACC2 2/2 mice (Supplemental Fig. 4 ),
suggesting that the antiobesity phenotypes of ACC2
2/2 mice might be linked with metabolism in adipose tissue. In Reduced malonyl-CoA content in ACC2 deletion triggers activation of CPT1 and enhancement of long-chain acyl-CoAs entry into the FAO pathway, leading to a reduced IMCL pool. In ACC2-deleted skeletal muscle, both the TCA cycle function and acetylcarnitine production work actively, leading to a decreased acetyl-CoA pool despite a higher rate of FAO. As a result, enhanced IMCL degradation does not inhibit PDH activity and glucose metabolism in ACC2 deletion. LC, long-chain; PDH, pyruvate dehydrogenase.
addition, ACC2 has been reported to play a significant role in hepatic metabolism (53, 54) . Although our investigations revealed important connections between enhanced lipid reduction and improved insulin sensitivity in ACC2 deletion with a focus on skeletal muscle metabolism, additional studies focusing on adipose tissue and liver are warranted to fully understand the beneficial effect of ACC2 deletion on whole-body energy homeostasis. In summary, we revealed that global deletion of ACC2 enhances lipid disposal without competing with glucose metabolism at the whole-body and skeletal muscle levels. This successful lipid reduction is characterized by a decreased acetyl-CoA pool in skeletal muscle, which is accounted for by enhanced TCA cycle activity and acetyl-CoA conversion into acetylcarnitine. These mitochondrial pathways related to acetyl-CoA metabolism work actively even under conditions of continuous lipid oversupply, and thus ACC2 deletion prevents HFDinduced IMCL accumulation and insulin resistance. Our findings offer new mechanistic insight into the improvement of insulin resistance by ACC2 inhibition and provide additional evidence that ACC2 is a potential target for treating type 2 diabetes.
